Technical Analysis: 2-(4-Aminophenyl)Acetonitrile Synthesis and Impurity Control
- [Reaction Kinetics] Optimized reduction pathways ensure consistent molar yields and minimize side reactions during scale-up.
- [Sourcing Stability] Direct factory supply chains guarantee tonnage availability and secure logistics for global distribution.
- [Regulatory Alignment] Comprehensive documentation supports REACH and TSCA compliance for seamless market entry.
2-(4-Aminophenyl)acetonitrile (CAS: 3544-25-0) serves as a critical chemical building block in the synthesis of complex pharmaceutical intermediates, including DPP-4 inhibitors and kinase inhibitors. For process chemists and procurement officers, understanding the nuanced synthesis route and associated impurity profiles is essential for maintaining industrial purity in final drug substances. As a premier global manufacturer, NINGBO INNO PHARMCHEM CO.,LTD. delivers this intermediate with rigorous quality controls tailored for large-scale production.
Optimizing 2-(4-Aminophenyl)acetonitrile Synthesis Route Yields
The primary manufacturing process for 4-Aminobenzyl cyanide typically involves the catalytic hydrogenation of 4-nitrophenylacetonitrile. Achieving high reaction yields requires precise control over hydrogen pressure, catalyst selection (often Pd/C or Raney Nickel), and solvent systems. Inadequate control can lead to over-reduction or the formation of secondary amines. Our internal data suggests that maintaining strict temperature gradients during the exothermic reduction phase is vital for maximizing conversion rates while preventing the formation of azo-type byproducts.
Furthermore, the choice of solvent significantly impacts the isolation efficiency. Polar protic solvents often facilitate better solubility of the nitro precursor, whereas switching to less polar systems during crystallization can enhance the recovery of the final amine. By refining these parameters, manufacturers can achieve batch-to-batch consistency that meets the demanding specifications of modern medicinal chemistry campaigns.
Controlling Acidity and Ammonia Impurity Profiles
Impurity management is a cornerstone of producing commercial grade intermediates. The most common contaminants in this synthesis include residual starting materials, incomplete reduction products, and traces of ammonia or cyanide species. Analytical methods such as HPLC and GC-MS are employed to detect these deviations at ppm levels. Specifically, controlling the acidity is crucial, as residual acids from the neutralization step can catalyze polymerization during storage.
Additionally, the potential for cyanide metabolism requires careful monitoring of free cyanide ions throughout the production lifecycle. Advanced purification techniques, including recrystallization from optimized solvent pairs, are utilized to reduce these specific impurities below identification thresholds. This attention to detail ensures that the impurity profile remains within acceptable limits for downstream coupling reactions, safeguarding the integrity of the final active pharmaceutical ingredient.
Scaling Reaction Conditions for Industrial Purity
Transitioning from laboratory synthesis to tonnage quantities introduces challenges related to heat transfer and mixing efficiency. Scalability requires robust engineering controls to maintain the same reaction kinetics observed in pilot batches. For procurement teams, securing a reliable factory supply means partnering with manufacturers who have proven capabilities in handling hazardous nitriles safely and efficiently.
When sourcing high-purity 2-(4-Aminophenyl)acetonitrile, buyers should verify that the supplier offers comprehensive technical support alongside competitive bulk price structures. NINGBO INNO PHARMCHEM CO.,LTD. ensures that every shipment is accompanied by a batch-specific Certificate of Analysis (COA) and Safety Data Sheet (SDS), facilitating smooth regulatory filings and quality assurance audits.
| Parameter | Specification | Test Method |
|---|---|---|
| CAS Number | 3544-25-0 | Registry |
| Molecular Formula | C8H8N2 | Calculated |
| Molecular Weight | 132.163 g/mol | MS |
| Melting Point | 45-48 °C | DSC / Capillary |
| Boiling Point | 312.0 °C at 760 mmHg | Distillation |
| Density | 1.1 ± 0.1 g/cm³ | Pychnometer |
| Purity (HPLC) | > 98.5% (Commercial Grade) | HPLC Area % |
| Appearance | Crystalline Powder (Yellow to Brown) | Visual |
For organizations requiring validated supply chains, it is imperative to establish clear communication regarding lead times and packaging requirements. Whether for clinical trial materials or commercial production, the stability of the supply line directly impacts project timelines. We recommend initiating early dialogue with our technical sales team to align production schedules with your development milestones.
To ensure your project remains on track, please contact our technical sales team for a batch-specific COA, SDS, or bulk pricing quote. Our experts are ready to assist with custom synthesis requests and regulatory documentation needs.